Header Logo

Connection

Ian Sanne to HIV Infections

This is a "connection" page, showing publications Ian Sanne has written about HIV Infections.
Connection Strength

7,222
  1. Voluntary medical male circumcision in selected provinces in South Africa: Outcomes from a programmatic setting. PLoS One. 2022; 17(9):e0270545.
    View in: PubMed
    Score: 0,226
  2. Impact of direct-acting antiviral treatment of hepatitis C on the quality of life of adults in Ukraine. BMC Infect Dis. 2022 Jul 27; 22(1):650.
    View in: PubMed
    Score: 0,223
  3. Varying intervals of antiretroviral medication dispensing to improve outcomes for HIV patients (The INTERVAL Study): study protocol for a randomized controlled trial. Trials. 2017 Oct 13; 18(1):476.
    View in: PubMed
    Score: 0,160
  4. Cohort profile: the Right to Care Clinical HIV Cohort, South Africa. BMJ Open. 2017 06 10; 7(6):e015620.
    View in: PubMed
    Score: 0,156
  5. Changing models of care to improve progression through the HIV treatment cascade in different populations. Curr Opin HIV AIDS. 2015 Nov; 10(6):447-50.
    View in: PubMed
    Score: 0,140
  6. Impact of three empirical anti-tuberculosis treatment strategies for people initiating antiretroviral therapy. Int J Tuberc Lung Dis. 2014 Nov; 18(11):1340-6.
    View in: PubMed
    Score: 0,131
  7. Attrition through multiple stages of pre-treatment and ART HIV care in South Africa. PLoS One. 2014; 9(10):e110252.
    View in: PubMed
    Score: 0,130
  8. CD4 criteria improves the sensitivity of a clinical algorithm developed to identify viral failure in HIV-positive patients on antiretroviral therapy. J Int AIDS Soc. 2014; 17:19139.
    View in: PubMed
    Score: 0,129
  9. A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
    View in: PubMed
    Score: 0,120
  10. The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa. PLoS One. 2013; 8(8):e71719.
    View in: PubMed
    Score: 0,120
  11. Impact of nutritional supplementation on immune response, body mass index and bioelectrical impedance in HIV-positive patients starting antiretroviral therapy. Nutr J. 2013 Aug 06; 12:111.
    View in: PubMed
    Score: 0,120
  12. Cohort profile: the Themba Lethu Clinical Cohort, Johannesburg, South Africa. Int J Epidemiol. 2013 Apr; 42(2):430-9.
    View in: PubMed
    Score: 0,109
  13. Effectiveness and safety of 30 mg versus 40 mg stavudine regimens: a cohort study among HIV-infected adults initiating HAART in South Africa. J Int AIDS Soc. 2012 Mar 12; 15(1):13.
    View in: PubMed
    Score: 0,109
  14. Least among equals. Clin Infect Dis. 2012 Mar; 54(6):876-7.
    View in: PubMed
    Score: 0,109
  15. Increased risk of mortality and loss to follow-up among HIV-positive patients with oropharyngeal candidiasis and malnutrition before antiretroviral therapy initiation: a retrospective analysis from a large urban cohort in Johannesburg, South Africa. Oral Surg Oral Med Oral Pathol Oral Radiol. 2012 Mar; 113(3):362-72.
    View in: PubMed
    Score: 0,109
  16. Pregnancy and virologic response to antiretroviral therapy in South Africa. PLoS One. 2011; 6(8):e22778.
    View in: PubMed
    Score: 0,104
  17. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. J Acquir Immune Defic Syndr. 2011 Apr; 56(4):349-55.
    View in: PubMed
    Score: 0,102
  18. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety. Clin Infect Dis. 2011 Jan 01; 52(1):128-37.
    View in: PubMed
    Score: 0,100
  19. Economic outcomes of patients receiving antiretroviral therapy for HIV/AIDS in South Africa are sustained through three years on treatment. PLoS One. 2010 Sep 14; 5(9):e12731.
    View in: PubMed
    Score: 0,098
  20. Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
    View in: PubMed
    Score: 0,097
  21. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):500-6.
    View in: PubMed
    Score: 0,095
  22. Using vital registration data to update mortality among patients lost to follow-up from ART programmes: evidence from the Themba Lethu Clinic, South Africa. Trop Med Int Health. 2010 Apr; 15(4):405-13.
    View in: PubMed
    Score: 0,094
  23. Complex regional pain syndrome in a HIV seropositive patient starting antiretroviral therapy. J Clin Rheumatol. 2009 Oct; 15(7):371-2.
    View in: PubMed
    Score: 0,092
  24. Diverse and high prevalence of human papillomavirus associated with a significant high rate of cervical dysplasia in human immunodeficiency virus-infected women in Johannesburg, South Africa. Acta Cytol. 2009 Jan-Feb; 53(1):10-7.
    View in: PubMed
    Score: 0,087
  25. The outcomes and outpatient costs of different models of antiretroviral treatment delivery in South Africa. Trop Med Int Health. 2008 Aug; 13(8):1005-15.
    View in: PubMed
    Score: 0,084
  26. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 Mar 15; 191(6):825-9.
    View in: PubMed
    Score: 0,067
  27. Research as a path to wide-scale implementation of antiretroviral therapy in Africa. J HIV Ther. 2004 Sep; 9(3):65-8.
    View in: PubMed
    Score: 0,065
  28. Trends in COVID-19 admissions and deaths among people living with HIV in South Africa: analysis of national surveillance data. Lancet HIV. 2024 Feb; 11(2):e96-e105.
    View in: PubMed
    Score: 0,062
  29. The cardiovascular consequences of HIV and antiretroviral therapy. Cardiovasc J S Afr. 2003 Sep-Oct; 14(5):225-9.
    View in: PubMed
    Score: 0,060
  30. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349). Clin Infect Dis. 2023 02 08; 76(3):e580-e589.
    View in: PubMed
    Score: 0,058
  31. Results of a phase 2 clinical trial at 48 weeks (AI424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003 Jan 01; 32(1):18-29.
    View in: PubMed
    Score: 0,058
  32. Applying machine learning and predictive modeling to retention and viral suppression in South African HIV treatment cohorts. Sci Rep. 2022 07 26; 12(1):12715.
    View in: PubMed
    Score: 0,056
  33. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022 03 19; 399(10330):1141-1153.
    View in: PubMed
    Score: 0,054
  34. Mitigation strategies to safely conduct HIV treatment research in the context of COVID-19. J Int AIDS Soc. 2022 02; 25(2):e25882.
    View in: PubMed
    Score: 0,054
  35. Multimonth dispensing of up to 6 months of antiretroviral therapy in Malawi and Zambia (INTERVAL): a cluster-randomised, non-blinded, non-inferiority trial. Lancet Glob Health. 2021 05; 9(5):e628-e638.
    View in: PubMed
    Score: 0,051
  36. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? Int J Infect Dis. 2001; 5(1):43-8.
    View in: PubMed
    Score: 0,050
  37. Twelve-Month Outcomes of Community-Based Differentiated Models of Multimonth Dispensing of ART Among Stable HIV-Infected Adults in Lesotho: A Cluster-Randomized Noninferiority Trial. J Acquir Immune Defic Syndr. 2020 11 01; 85(3):280-291.
    View in: PubMed
    Score: 0,049
  38. Treatment outcomes and costs of a simplified antiviral treatment strategy for hepatitis C among monoinfected and HIV and/or hepatitis B virus-co-infected patients in Myanmar. J Viral Hepat. 2021 01; 28(1):147-158.
    View in: PubMed
    Score: 0,049
  39. Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Reader™ for rapid HIV testing in South Africa. BMC Infect Dis. 2020 May 04; 20(1):320.
    View in: PubMed
    Score: 0,048
  40. Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint. AIDS. 2020 04 01; 34(5):681-686.
    View in: PubMed
    Score: 0,048
  41. Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia. AIDS. 2020 03 01; 34(3):475-479.
    View in: PubMed
    Score: 0,047
  42. Growth curve modelling to determine distinct BMI trajectory groups in HIV-positive adults on antiretroviral therapy in South Africa. AIDS. 2019 11 01; 33(13):2049-2059.
    View in: PubMed
    Score: 0,046
  43. Treatment outcomes among HIV-positive orphaned and non-orphaned children on antiretroviral therapy in Johannesburg, South Africa. S Afr Med J. 2019 Aug 28; 109(9):679-685.
    View in: PubMed
    Score: 0,046
  44. HIV incidence, pregnancy, and implementation outcomes from the Sakh'umndeni safer conception project in South Africa: a prospective cohort study. Lancet HIV. 2019 07; 6(7):e438-e446.
    View in: PubMed
    Score: 0,045
  45. Human Immunodeficiency Virus Type 1 and Tuberculosis Coinfection in Multinational, Resource-limited Settings: Increased Neurological Dysfunction. Clin Infect Dis. 2019 05 02; 68(10):1739-1746.
    View in: PubMed
    Score: 0,045
  46. "Even if you're HIV-positive there's life after if you take your medication": experiences of people on long-term ART in South Africa: a short report. AIDS Care. 2019 08; 31(8):973-978.
    View in: PubMed
    Score: 0,044
  47. Prevalence, incidence, predictors, treatment, and control of hypertension among HIV-positive adults on antiretroviral treatment in public sector treatment programs in South Africa. PLoS One. 2018; 13(10):e0204020.
    View in: PubMed
    Score: 0,043
  48. Implementation of Option B and a fixed-dose combination antiretroviral regimen for prevention of mother-to-child transmission of HIV in South Africa: A model of uptake and adherence to care. PLoS One. 2018; 13(8):e0201955.
    View in: PubMed
    Score: 0,043
  49. Regimen durability in HIV-infected children and adolescents initiating first-line antiretroviral therapy in a large public sector HIV cohort in South Africa. Trop Med Int Health. 2018 06; 23(6):650-660.
    View in: PubMed
    Score: 0,042
  50. Predictors of switch to and early outcomes on third-line antiretroviral therapy at a large public-sector clinic in Johannesburg, South Africa. AIDS Res Ther. 2018 04 10; 15(1):10.
    View in: PubMed
    Score: 0,041
  51. Changing the South African national antiretroviral therapy guidelines: The role of cost modelling. PLoS One. 2017; 12(10):e0186557.
    View in: PubMed
    Score: 0,040
  52. Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. J Acquir Immune Defic Syndr. 2017 09 01; 76(1):65-73.
    View in: PubMed
    Score: 0,040
  53. Initiating antiretroviral therapy for HIV at a patient's first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS. 2017 Jul 17; 31(11):1611-1619.
    View in: PubMed
    Score: 0,039
  54. Client uptake of safer conception strategies: implementation outcomes from the Sakh'umndeni Safer Conception Clinic in South Africa. J Int AIDS Soc. 2017 03 08; 20(Suppl 1):21291.
    View in: PubMed
    Score: 0,038
  55. Citizenship status and engagement in HIV care: an observational cohort study to assess the association between reporting a national ID number and retention in public-sector HIV care in Johannesburg, South Africa. BMJ Open. 2017 01 24; 7(1):e013908.
    View in: PubMed
    Score: 0,038
  56. Evaluation of the Tsima community mobilization intervention to improve engagement in HIV testing and care in South Africa: study protocol for a cluster randomized trial. Implement Sci. 2017 Jan 17; 12(1):9.
    View in: PubMed
    Score: 0,038
  57. Imputing HIV treatment start dates from routine laboratory data in South Africa: a validation study. BMC Health Serv Res. 2017 Jan 17; 17(1):41.
    View in: PubMed
    Score: 0,038
  58. Tenofovir stock shortages have limited impact on clinic- and patient-level HIV treatment outcomes in public sector clinics in South Africa. Trop Med Int Health. 2017 02; 22(2):241-251.
    View in: PubMed
    Score: 0,038
  59. Treatment Outcomes and Costs of Providing Antiretroviral Therapy at a Primary Health Clinic versus a Hospital-Based HIV Clinic in South Africa. PLoS One. 2016; 11(12):e0168118.
    View in: PubMed
    Score: 0,038
  60. Moderate Levels of Pre-Treatment HIV-1 Antiretroviral Drug Resistance Detected in the First South African National Survey. PLoS One. 2016; 11(12):e0166305.
    View in: PubMed
    Score: 0,038
  61. Treatment outcomes of over 1000 patients on second-line, protease inhibitor-based antiretroviral therapy from four public-sector HIV treatment facilities across Johannesburg, South Africa. Trop Med Int Health. 2017 02; 22(2):221-231.
    View in: PubMed
    Score: 0,038
  62. Prevalence of Antiretroviral Drug Resistance in Patients Who Are Not Responding to Protease Inhibitor-Based Treatment: Results From the First National Survey in South Africa. J Infect Dis. 2016 Dec 15; 214(12):1826-1830.
    View in: PubMed
    Score: 0,037
  63. HIV-1 antiretroviral drug resistance patterns in patients failing NNRTI-based treatment: results from a national survey in South Africa. J Antimicrob Chemother. 2017 01; 72(1):210-219.
    View in: PubMed
    Score: 0,037
  64. Marginal Structural Models to Assess Delays in Second-Line HIV Treatment Initiation in South Africa. PLoS One. 2016; 11(8):e0161469.
    View in: PubMed
    Score: 0,037
  65. Incident tuberculosis in HIV-positive children, adolescents and adults on antiretroviral therapy in South Africa. Int J Tuberc Lung Dis. 2016 08; 20(8):1040-5.
    View in: PubMed
    Score: 0,037
  66. The High Cost of HIV-Positive Inpatient Care at an Urban Hospital in Johannesburg, South Africa. PLoS One. 2016; 11(2):e0148546.
    View in: PubMed
    Score: 0,036
  67. Implementation and Operational Research: Implementation of Multiple Point-of-Care Testing in 2 HIV Antiretroviral Treatment Clinics in South Africa. J Acquir Immune Defic Syndr. 2016 Feb 01; 71(2):e34-43.
    View in: PubMed
    Score: 0,036
  68. Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol. 2016 07; 100(1):223-31.
    View in: PubMed
    Score: 0,035
  69. Brief Report: Does Most Mortality in Patients on ART Occur in Care or After Lost to Follow-Up? Evidence From the Themba Lethu Clinic, South Africa. J Acquir Immune Defic Syndr. 2015 Nov 01; 70(3):323-8.
    View in: PubMed
    Score: 0,035
  70. "I don't know if this is right … but this is what I'm offering": healthcare provider knowledge, practice, and attitudes towards safer conception for HIV-affected couples in the context of Southern African guidelines. AIDS Care. 2016; 28(3):390-6.
    View in: PubMed
    Score: 0,035
  71. Acceptability and preferences for safer conception HIV prevention strategies: a qualitative study. Int J STD AIDS. 2016 10; 27(11):984-92.
    View in: PubMed
    Score: 0,035
  72. Predictive and prognostic properties of TB-LAM among HIV-positive patients initiating ART in Johannesburg, South Africa. Pan Afr Med J. 2015; 22:4.
    View in: PubMed
    Score: 0,035
  73. The patient impact of point-of-care vs. laboratory placement of Xpert(®) MTB/RIF. Int J Tuberc Lung Dis. 2015 Jul; 19(7):811-6.
    View in: PubMed
    Score: 0,034
  74. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa. J Int AIDS Soc. 2014; 17:19065.
    View in: PubMed
    Score: 0,033
  75. High uptake of systematic HIV counseling and testing and TB symptom screening at a primary care clinic in South Africa. PLoS One. 2014; 9(9):e105428.
    View in: PubMed
    Score: 0,032
  76. Impact of systematic HIV testing on case finding and retention in care at a primary care clinic in South Africa. Trop Med Int Health. 2014 Dec; 19(12):1411-9.
    View in: PubMed
    Score: 0,032
  77. Implementation of a safer conception service for HIV-affected couples in South Africa. AIDS. 2014 Jul; 28 Suppl 3:S277-85.
    View in: PubMed
    Score: 0,032
  78. Xpert MTB/RIF as a measure of sputum bacillary burden. Variation by HIV status and immunosuppression. Am J Respir Crit Care Med. 2014 Jun 01; 189(11):1426-34.
    View in: PubMed
    Score: 0,032
  79. A home tracing program for contacts of people with tuberculosis or HIV and patients lost to care. Int J Tuberc Lung Dis. 2014 May; 18(5):534-40.
    View in: PubMed
    Score: 0,032
  80. Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs. J Acquir Immune Defic Syndr. 2014 Apr 01; 65(4):423-8.
    View in: PubMed
    Score: 0,031
  81. Incidence and predictors of herpes zoster among antiretroviral therapy-naïve patients initiating HIV treatment in Johannesburg, South Africa. Int J Infect Dis. 2014 Jun; 23:56-62.
    View in: PubMed
    Score: 0,031
  82. Impact of choice of NRTI in first-line antiretroviral therapy: a cohort analysis of stavudine vs. tenofovir. Trop Med Int Health. 2014 May; 19(5):490-8.
    View in: PubMed
    Score: 0,031
  83. Poor CD4 recovery and risk of subsequent progression to AIDS or death despite viral suppression in a South African cohort. J Int AIDS Soc. 2014; 17:18651.
    View in: PubMed
    Score: 0,031
  84. Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection. PLoS One. 2014; 9(2):e89925.
    View in: PubMed
    Score: 0,031
  85. Effect of antiretroviral therapy on patients' economic well being: five-year follow-up. AIDS. 2014 Jan 28; 28(3):417-24.
    View in: PubMed
    Score: 0,031
  86. Regulatory challenges associated with conducting multicountry clinical trials in resource-limited settings. J Acquir Immune Defic Syndr. 2014 Jan 01; 65 Suppl 1:S29-31.
    View in: PubMed
    Score: 0,031
  87. Low prevalence of liver disease but regional differences in HBV treatment characteristics mark HIV/HBV co-infection in a South African HIV clinical trial. PLoS One. 2013; 8(12):e74900.
    View in: PubMed
    Score: 0,031
  88. Increases in regimen durability associated with the introduction of tenofovir at a large public-sector clinic in Johannesburg, South Africa. J Int AIDS Soc. 2013 Nov 19; 16:18794.
    View in: PubMed
    Score: 0,031
  89. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med. 2013 Oct 31; 369(18):1715-25.
    View in: PubMed
    Score: 0,030
  90. Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis. 2013 Nov 15; 208(10):1624-8.
    View in: PubMed
    Score: 0,030
  91. Impact and costs of algorithms for the diagnosis of adults with pulmonary tuberculosis in South Africa. S Afr Med J. 2013 Jul; 103(7):436.
    View in: PubMed
    Score: 0,030
  92. Diagnostic accuracy and effectiveness of the Xpert MTB/RIF assay for the diagnosis of HIV-associated lymph node tuberculosis. Eur J Clin Microbiol Infect Dis. 2013 Nov; 32(11):1409-15.
    View in: PubMed
    Score: 0,029
  93. Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study. Clin Infect Dis. 2013 Aug; 57(4):586-93.
    View in: PubMed
    Score: 0,029
  94. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013 Feb 20; 27(4):645-50.
    View in: PubMed
    Score: 0,029
  95. The interplay between CD4 cell count, viral load suppression and duration of antiretroviral therapy on mortality in a resource-limited setting. Trop Med Int Health. 2013 May; 18(5):619-31.
    View in: PubMed
    Score: 0,029
  96. Patient retention from HIV diagnosis through one year on antiretroviral therapy at a primary health care clinic in Johannesburg, South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e39-46.
    View in: PubMed
    Score: 0,029
  97. Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa. J Acquir Immune Defic Syndr. 2013 Feb 01; 62(2):e55-7.
    View in: PubMed
    Score: 0,029
  98. Linkage to care and treatment for TB and HIV among people newly diagnosed with TB or HIV-associated TB at a large, inner city South African hospital. PLoS One. 2013; 8(1):e49140.
    View in: PubMed
    Score: 0,029
  99. Diagnosing Xpert MTB/RIF negative TB: impact and cost of alternative algorithms for South Africa. S Afr Med J. 2013 Jan 14; 103(2):101-6.
    View in: PubMed
    Score: 0,029
  100. The early effects of stavudine compared with tenofovir on adipocyte gene expression, mitochondrial DNA copy number and metabolic parameters in South African HIV-infected patients: a randomized trial. HIV Med. 2013 Apr; 14(4):217-25.
    View in: PubMed
    Score: 0,028
  101. Implementation of Xpert MTB/RIF for routine point-of-care diagnosis of tuberculosis at the primary care level. S Afr Med J. 2012 Sep 07; 102(10):805-7.
    View in: PubMed
    Score: 0,028
  102. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. J Acquir Immune Defic Syndr. 2012 Aug 15; 60 Suppl 3:S96-104.
    View in: PubMed
    Score: 0,028
  103. Antiretroviral therapy initiation during tuberculosis treatment and HIV-RNA and CD4 T-lymphocyte responses. Int J Tuberc Lung Dis. 2012 Oct; 16(10):1358-64.
    View in: PubMed
    Score: 0,028
  104. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors. Clin Infect Dis. 2012 Sep; 55(5):737-45.
    View in: PubMed
    Score: 0,028
  105. Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification. PLoS Med. 2012; 9(4):e1001207.
    View in: PubMed
    Score: 0,027
  106. Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy. Antivir Ther. 2012; 17(2):313-20.
    View in: PubMed
    Score: 0,027
  107. Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection. J Acquir Immune Defic Syndr. 2011 Nov 01; 58(3):309-18.
    View in: PubMed
    Score: 0,027
  108. Outcomes of stable HIV-positive patients down-referred from a doctor-managed antiretroviral therapy clinic to a nurse-managed primary health clinic for monitoring and treatment. AIDS. 2011 Oct 23; 25(16):2027-36.
    View in: PubMed
    Score: 0,026
  109. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20; 365(16):1482-91.
    View in: PubMed
    Score: 0,026
  110. Poorer ART outcomes with increasing age at a large public sector HIV clinic in Johannesburg, South Africa. J Int Assoc Physicians AIDS Care (Chic). 2012 Jan-Feb; 11(1):57-65.
    View in: PubMed
    Score: 0,026
  111. A longitudinal study of stavudine-associated toxicities in a large cohort of South African HIV infected subjects. BMC Infect Dis. 2011 Sep 17; 11:244.
    View in: PubMed
    Score: 0,026
  112. Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir. AIDS. 2011 Aug 24; 25(13):1603-9.
    View in: PubMed
    Score: 0,026
  113. Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study. J Int AIDS Soc. 2011 Jul 29; 14:37.
    View in: PubMed
    Score: 0,026
  114. Comparison of Xpert MTB/RIF with other nucleic acid technologies for diagnosing pulmonary tuberculosis in a high HIV prevalence setting: a prospective study. PLoS Med. 2011 Jul; 8(7):e1001061.
    View in: PubMed
    Score: 0,026
  115. A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. 2011 Oct; 17(5):438-47.
    View in: PubMed
    Score: 0,026
  116. Treatment outcomes and cost-effectiveness of shifting management of stable ART patients to nurses in South Africa: an observational cohort. PLoS Med. 2011 Jul; 8(7):e1001055.
    View in: PubMed
    Score: 0,026
  117. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011 Aug 11; 365(6):493-505.
    View in: PubMed
    Score: 0,026
  118. Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection. PLoS One. 2011; 6(6):e21450.
    View in: PubMed
    Score: 0,026
  119. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc. 2011 May 15; 14:24.
    View in: PubMed
    Score: 0,026
  120. Efavirenz and rifampicin in the South African context: is there a need to dose-increase efavirenz with concurrent rifampicin therapy? Antivir Ther. 2011; 16(4):527-34.
    View in: PubMed
    Score: 0,025
  121. The importance of clinic attendance in the first six months on antiretroviral treatment: a retrospective analysis at a large public sector HIV clinic in South Africa. J Int AIDS Soc. 2010 Dec 07; 13:49.
    View in: PubMed
    Score: 0,025
  122. Xpert(®) MTB/RIF for point-of-care diagnosis of TB in high-HIV burden, resource-limited countries: hype or hope? Expert Rev Mol Diagn. 2010 Oct; 10(7):937-46.
    View in: PubMed
    Score: 0,025
  123. Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women. J Int AIDS Soc. 2010 Sep 07; 13:33.
    View in: PubMed
    Score: 0,024
  124. Prolonged deferral of antiretroviral therapy in the SAPIT trial: did we need a clinical trial to tell us that this would increase mortality? S Afr Med J. 2010 Sep 07; 100(9):566, 568, 570-1.
    View in: PubMed
    Score: 0,024
  125. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
    View in: PubMed
    Score: 0,024
  126. Early loss to follow up after enrolment in pre-ART care at a large public clinic in Johannesburg, South Africa. Trop Med Int Health. 2010 Jun; 15 Suppl 1:43-7.
    View in: PubMed
    Score: 0,024
  127. Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr. 2010 Apr 01; 53(4):480-4.
    View in: PubMed
    Score: 0,024
  128. Comparison of once-daily versus twice-daily combination antiretroviral therapy in treatment-naive patients: results of AIDS clinical trials group (ACTG) A5073, a 48-week randomized controlled trial. Clin Infect Dis. 2010 Apr 01; 50(7):1041-52.
    View in: PubMed
    Score: 0,024
  129. The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa. AIDS. 2010 Mar 27; 24(6):915-9.
    View in: PubMed
    Score: 0,024
  130. Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa? J Acquir Immune Defic Syndr. 2009 Dec; 52(5):655-6.
    View in: PubMed
    Score: 0,023
  131. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy. Clin Infect Dis. 2009 Jun 01; 48(11):1617-23.
    View in: PubMed
    Score: 0,022
  132. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One. 2009; 4(5):e5575.
    View in: PubMed
    Score: 0,022
  133. Evaluating nurses' implementation of an infant-feeding counseling protocol for HIV-infected mothers: The Ban Study in Lilongwe, Malawi. AIDS Educ Prev. 2009 Apr; 21(2):141-55.
    View in: PubMed
    Score: 0,022
  134. Effect of pulmonary tuberculosis on mortality in patients receiving HAART. AIDS. 2009 Mar 27; 23(6):707-15.
    View in: PubMed
    Score: 0,022
  135. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis. 2009 Jul; 13(4):488-92.
    View in: PubMed
    Score: 0,022
  136. Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. JAMA. 2008 Jul 23; 300(4):423-30.
    View in: PubMed
    Score: 0,021
  137. Characteristics of patients accessing care and treatment for HIV/AIDS at public and nongovernmental sites in South Africa. J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug; 7(4):200-7.
    View in: PubMed
    Score: 0,021
  138. Differences in normal activities, job performance and symptom prevalence between patients not yet on antiretroviral therapy and patients initiating therapy in South Africa. AIDS. 2008 Jul; 22 Suppl 1:S131-9.
    View in: PubMed
    Score: 0,021
  139. The prevalence of hepatitis B co-infection in a South African urban government HIV clinic. S Afr Med J. 2008 Jul; 98(7):541-4.
    View in: PubMed
    Score: 0,021
  140. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr. 2007 Sep 01; 46(1):91-100.
    View in: PubMed
    Score: 0,020
  141. Cost to patients of obtaining treatment for HIV/AIDS in South Africa. S Afr Med J. 2007 Jul; 97(7):524-9.
    View in: PubMed
    Score: 0,020
  142. High tuberculosis and HIV coinfection rate, Johannesburg. Emerg Infect Dis. 2007 May; 13(5):795-6.
    View in: PubMed
    Score: 0,019
  143. Long-term (120-Week) antiviral efficacy and tolerability of fosamprenavir/ritonavir once daily in therapy-naive patients with HIV-1 infection: an uncontrolled, open-label, single-arm follow-on study. Clin Ther. 2006 May; 28(5):745-54.
    View in: PubMed
    Score: 0,018
  144. Hard choices: rationing antiretroviral therapy for HIV/AIDS in Africa. Lancet. 2005 Jan 22-28; 365(9456):354-6.
    View in: PubMed
    Score: 0,017
  145. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients. J Infect Dis. 2004 Jul 15; 190(2):280-4.
    View in: PubMed
    Score: 0,016
  146. Failure of lopinavir-ritonavir (Kaletra)-containing regimen in an antiretroviral-naive patient. AIDS. 2004 Apr 30; 18(7):1084-5.
    View in: PubMed
    Score: 0,016
  147. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results. AIDS. 2003 Dec 05; 17(18):2603-14.
    View in: PubMed
    Score: 0,015
  148. Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients. J Infect Dis. 2003 Dec 01; 188(11):1652-8.
    View in: PubMed
    Score: 0,015
  149. T cells containing T cell receptor excision circles are inversely related to HIV replication and are selectively and rapidly released into circulation with antiretroviral treatment. AIDS. 2003 May 23; 17(8):1145-9.
    View in: PubMed
    Score: 0,015
  150. Challenges in delivering antiretroviral treatment in resource poor countries. AIDS. 2002; 16 Suppl 4:S177-87.
    View in: PubMed
    Score: 0,013
  151. Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women. Carcinogenesis. 2019 04 29; 40(2):225-233.
    View in: PubMed
    Score: 0,011
  152. Does Disseminated Nontuberculous Mycobacterial Disease Cause False-Positive Determine TB-LAM Lateral Flow Assay Results? A Retrospective Review. Clin Infect Dis. 2017 10 01; 65(7):1226-1228.
    View in: PubMed
    Score: 0,010
  153. Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infect Dis. 2016 11 08; 16(1):661.
    View in: PubMed
    Score: 0,009
  154. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol. 2016 08; 22(4):472-8.
    View in: PubMed
    Score: 0,009
  155. The impact of Xpert(®) MTB/RIF in sparsely populated rural settings. Int J Tuberc Lung Dis. 2015 Apr; 19(4):392-8.
    View in: PubMed
    Score: 0,008
  156. Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study. Clin Infect Dis. 2015 Jun 15; 60(12):1860-3.
    View in: PubMed
    Score: 0,008
  157. Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB. J Clin Microbiol. 2014 Apr; 52(4):1052-9.
    View in: PubMed
    Score: 0,008
  158. Identification of Mycobacterium tuberculosis from pericardial fluid using the new Xpert MTB/RIF assay. BMJ Case Rep. 2013 Aug 28; 2013.
    View in: PubMed
    Score: 0,008
  159. Time to treatment and patient outcomes among TB suspects screened by a single point-of-care xpert MTB/RIF at a primary care clinic in Johannesburg, South Africa. PLoS One. 2013; 8(6):e65421.
    View in: PubMed
    Score: 0,007
  160. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006 Sep 15; 43(6):783-6.
    View in: PubMed
    Score: 0,005
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.